Posted in | News | Biofuels | Water | Energy

Biodiesel Pilot Plant From Catilin Receives Renewable Energy Award

Catilin, Inc., a leading catalyst technology company for biofuels, announced today a Demonstration Fund award of $150,000 by the Iowa Department of Economic Development. The award is targeted for the upgrade of Catilin's biodiesel pilot plant, from batch to continuous operation mode. Operation of the pilot plant in the continuous mode is the final step in the rigorous commercialization process of the world's first heterogeneous (solid) biodiesel catalyst: Catilin's T300 Biodiesel Catalyst.

Biodiesel is commonly produced using a homogeneous (liquid) catalyst, such as sodium hydroxide or sodium methylate. These catalysts require excessive amounts of water, energy, toxic chemicals, and equipment to produce the biodiesel and glycerin co-products. Catilin's heterogeneous catalyst, on the other hand, does not suffer these traits and is also non-toxic, a critical issue throughout the U.S. and around the globe. Additionally, the T300 Catalyst can be used in existing plants with minimal modification as it reacts at common operational temperatures and pressure.

"We are pleased to receive the Iowa Demonstration Fund award. It validates our extensive and successful testing in our lab and now in our continuous process flow pilot plant. Our pilot plant produces 300,000 gallons of high-quality biodiesel per year utilizing Catilin's ground-breaking T300 Catalyst," said Larry Lenhart, Catilin President and CEO.

Catilin's pilot plant is located within the BECON (Biomass Energy Conversion) facility outside of Ames, IA. The pilot plant is open to visitors, prospective partners and customers.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.